CytomX Reports Steep Revenue Decline, Net Loss, and Major Partnership Terminations Amidst Highly Dilutive Capital Raise

summarizeSummary

CytomX Therapeutics reported a substantial revenue decline and net loss for 2025, driven by multiple collaboration terminations and pauses, alongside a highly dilutive equity offering to extend its cash runway.

check_boxKey Events

• Significant Revenue Decline and Net Loss

  Total revenue decreased by 45% to $76.2 million in 2025 from $138.1 million in 2024, resulting in a net loss of $17.4 million in 2025, a significant reversal from a net income of $31.9 million in 2024.

• Highly Dilutive Public Offering and ATM Sales

  In May 2025, the company completed an underwritten public offering of 76.9 million shares at $1.30 per share, generating $93.4 million in net proceeds. Additionally, 4.9 million shares were sold via an At-The-Market (ATM) program in 2025 for $16.3 million. These offerings more than doubled the outstanding common stock from 80.1 million shares at year-end 2024 to 170.2 million shares at year-end 2025, indicating substantial dilution.

• Multiple Collaboration Terminations and Pauses

  The Astellas collaboration was terminated in March 2026 (effective Q2 2026), and Moderna's collaboration programs were paused in Q1 2026 due to budget considerations. Earlier, Amgen terminated development of CX-904 (March 2025) and another preclinical product (April 2025), and Bristol Myers Squibb terminated its CTLA-4 program (March 2024) and another preclinical target (May 2025). These represent significant losses of non-dilutive funding and development support.

• Positive Varseta-M Clinical Data Update

  The company announced positive interim results from the Phase 1 dose expansions for Varseta-M in late-line metastatic colorectal cancer (CRC) in March 2026, showing confirmed overall response rates of 20% at 8.6 mg/kg and 32% at 10 mg/kg, with median progression-free survival of 6.8 and 7.1 months, respectively. Plans are underway to align with the FDA on a potential registrational study in 2026.

auto_awesomeAnalysis

CytomX Therapeutics' annual report reveals a challenging financial year marked by a significant revenue drop and a swing to a net loss. The company undertook a highly dilutive public offering in May 2025, issuing shares equivalent to over 96% of its prior outstanding common stock, and continued to sell shares via its ATM program to bolster its cash position. Critically, multiple key collaboration agreements, including with Astellas and Moderna, have been terminated or paused, signaling a significant setback in its partnership-driven funding model. While the company reported positive interim Phase 1 clinical data for its lead candidate, Varseta-M, and progress for CX-801, these clinical advancements are overshadowed by the substantial financial and strategic challenges, including the need for further capital to extend its runway beyond Q2 2027.